In the U.S. alone, 2.8 million people sustain a traumatic brain injury (TBI) each year and seek medical care.1,2 However, there are no FDA approved therapies for effective treatment of TBI (or concussion) patients. Current medications are limited to only reducing secondary damage to the brain following TBI, such as using diuretics to reduce the pressure inside the brain by increasing urine output.

Cell-type specific manipulation of neural circuits is required for the treatment of neurological disorders such as epilepsy and Parkinson’s disease. Precise control of neural circuits will enable the development of neuromodulation therapies for these debilitating conditions. Existing technologies to control neural activity offer limited possibilities.

BioBridge Global has been named one of two Prototype of the Year Award winners by the Medical Technology Enterprise Consortium (MTEC) for work done following a $7.8 million MTEC grant for the development of large-scale manufacturing capabilities for clinical-grade adult stem cells.

The award was presented at the MTEC Annual Meeting on March 4.

QualTex Laboratories, a subsidiary of San Antonio-based nonprofit BioBridge Global, has begun testing blood and plasma donations on its second automated track system, expanding its capabilities in its San Antonio laboratory.

The U.S. Food and Drug Administration has granted the South Texas Blood & Tissue Center (STBTC) approval to manufacture and distribute cold-stored platelets with a shelf life of 14 days for the treatment of actively bleeding patients when conventional platelets are not available, or their use is not practical. 

Platelets are a key blood component constantly in demand for treating severe bleeding, for example in trauma and maternal hemorrhage patients.   

The primary objective of this study is to assess the effect of GC4419 administered intravenously (IV) on the incidence and severity of severe oral mucositis (SOM) in subjects receiving post-operative or definitive therapy with single-agent cisplatin plus Intensity-Modulated Radiation Therapy (IMRT) for locally advanced, non-metastatic squamous cell carcinoma (SCC) of the oral cavity or oropharynx.

The objective of this proposal is to develop and characterize a novel Nanopore Microneedle Array that will enable cell transformation. Transformation will be enacted on 3D tissue volumes through cell electroporation and electrophoretic introduction of genetic material, causing a change in cell phenotype. In the proposal, the initial fabrication, testing, and proof-of-concept is described. Fabrication will be conducted at the Microelectronics Research Center on the J. J. Pickle Research Campus of the University of Texas at Austin.

The objective of this study is to define the amount and pattern of movement between the residual limb and the prosthetic socket during military relevant tasks and to leverage the information on limb/socket motion to develop algorithms lo identify these tasks for a controller used to adjust volume in an adaptable prosthetic socket.

Profiling MMV portfolio compound activity against the complete P. berghei liver stage.Scope includes compound screenings and portfolio compound testing where data will be delivered within 2 weeks of the end of the test run.

This is a multicenter, phase 3, double-blind, randomized, placebo-controlled study. Patients who qualify for study inclusion will be randomized in a 1:1:1 manner to receive MGL-3196 100 mg, MGL-3196 80 mg, or matching placebo given orally once daily in the morning for up to 54 months. If any patient has a Composite clinical outcome event on the Week 52 liver biopsy or any clinical composite event after Week 52 and prior to month 54 they will discontinue from the main study and will be allowed to participate in an open-label study on active treatment with MGL-3196.